PRTC Overview

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Wall Street analysts forecast PRTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRTC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

PureTech Health PLC revenue for the last quarter amounts to NaN USD, decreased

PureTech Health PLC. EPS for the last quarter amounts to USD, decreased

PureTech Health PLC (PRTC) has 56 emplpoyees as of March 21 2026.

Today PRTC has the market capitalization of 392.94M USD.